• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Worrying situation regarding the use of dexamethasone for COVID-19.

作者信息

Lim Michael Anthonius, Pranata Raymond

机构信息

Faculty of Medicine, Universitas Pelita Harapan, Tangerang, 15811, Indonesia.

Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia.

出版信息

Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620942131. doi: 10.1177/1753466620942131.

DOI:10.1177/1753466620942131
PMID:32684095
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7372607/
Abstract
摘要

相似文献

1
Worrying situation regarding the use of dexamethasone for COVID-19.关于地塞米松用于治疗新冠肺炎的令人担忧的情况。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620942131. doi: 10.1177/1753466620942131.
2
Dexamethasone for COVID-19: preliminary findings.地塞米松用于治疗新型冠状病毒肺炎：初步研究结果。
Drug Ther Bull. 2020 Sep;58(9):133. doi: 10.1136/dtb.2020.000045. Epub 2020 Jul 20.
3
Coronavirus breakthrough: dexamethasone is first drug shown to save lives.冠状病毒研究突破：地塞米松是首个被证明能挽救生命的药物。
Nature. 2020 Jun;582(7813):469. doi: 10.1038/d41586-020-01824-5.
4
Pros and cons of corticosteroid therapy for COVID-19 patients.COVID-19 患者使用皮质类固醇治疗的利弊。
Respir Physiol Neurobiol. 2020 Sep;280:103492. doi: 10.1016/j.resp.2020.103492. Epub 2020 Jul 10.
5
Use of glucocorticoids in patients with adrenal insufficiency and COVID-19 infection.糖皮质激素在肾上腺皮质功能不全合并新型冠状病毒肺炎感染患者中的应用。
Lancet Diabetes Endocrinol. 2020 Jun;8(6):472-473. doi: 10.1016/S2213-8587(20)30149-2. Epub 2020 Apr 23.
6
Dexamethasone: A boon for critically ill COVID-19 patients?地塞米松：对危重症COVID-19患者是福音吗？
Travel Med Infect Dis. 2020 Sep-Oct;37:101844. doi: 10.1016/j.tmaid.2020.101844. Epub 2020 Aug 10.
7
Dexamethasone in the management of covid -19.地塞米松在新冠病毒病治疗中的应用
BMJ. 2020 Jul 3;370:m2648. doi: 10.1136/bmj.m2648.
8
Emerging therapies for COVID-19 pneumonia.新型冠状病毒肺炎的新兴疗法。
Expert Opin Investig Drugs. 2020 Jul;29(7):633-637. doi: 10.1080/13543784.2020.1771694. Epub 2020 Jun 1.
9
Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases.一组患有风湿性疾病的COVID-19患者的临床病程、严重程度和死亡率。
Ann Rheum Dis. 2020 Dec;79(12):1659-1661. doi: 10.1136/annrheumdis-2020-218054. Epub 2020 Jun 30.
10
Coronavirus disease 2019 and the cardiovascular system: Impacts and implications.2019冠状病毒病与心血管系统：影响与启示。
Indian Heart J. 2020 Jan-Feb;72(1):1-6. doi: 10.1016/j.ihj.2020.03.006. Epub 2020 Apr 9.

引用本文的文献

1
Sivelestat protects against acute lung injury by up-regulating angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas receptors.西维来司他通过上调血管紧张素转换酶2/血管紧张素-（1-7）/Mas受体来预防急性肺损伤。
J Thorac Dis. 2024 Sep 30;16(9):6182-6195. doi: 10.21037/jtd-24-1281. Epub 2024 Sep 26.
2
Lidocaine and Dexamethasone, Ketamine and Dexamethasone, and Dexamethasone Alone in Tonsillectomy Complications.利多卡因与地塞米松、氯胺酮与地塞米松以及单独使用地塞米松在扁桃体切除术中的并发症情况
Adv Biomed Res. 2024 Jul 29;13:40. doi: 10.4103/abr.abr_234_22. eCollection 2024.
3
Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies.SARS-CoV-2 变异株的进化：对免疫逃逸、疫苗接种、治疗和诊断策略的影响。
Viruses. 2023 Apr 10;15(4):944. doi: 10.3390/v15040944.
4
Effects of tocilizumab and dexamethasone on the downregulation of proinflammatory cytokines and upregulation of antioxidants in the lungs in oleic acid-induced ARDS.托珠单抗和地塞米松对油酸诱导的 ARDS 中肺内促炎细胞因子下调和抗氧化剂上调的影响。
Respir Res. 2022 Sep 17;23(1):249. doi: 10.1186/s12931-022-02172-w.
5
Lack of Correlation Between Soluble Angiotensin-Converting Enzyme 2 and Inflammatory Markers in Hospitalized COVID-19 Patients with Hypertension.住院COVID-19高血压患者中可溶性血管紧张素转换酶2与炎症标志物之间缺乏相关性。
Infect Drug Resist. 2022 Aug 24;15:4799-4807. doi: 10.2147/IDR.S369771. eCollection 2022.
6
Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 - A systematic review and meta-analysis.二肽基肽酶-4（DPP-4）抑制剂与 COVID-19 患者死亡率降低相关——一项系统评价和荟萃分析。
Prim Care Diabetes. 2022 Feb;16(1):162-167. doi: 10.1016/j.pcd.2021.12.008. Epub 2021 Dec 13.
7
Comments on "Whole lung irradiation as a novel treatment for COVID-19: Interim results of an ongoing phase 2 trial in India".对《全肺照射作为COVID-19的一种新疗法：印度一项正在进行的2期试验的中期结果》的评论
Radiother Oncol. 2022 Feb;167:323-324. doi: 10.1016/j.radonc.2021.12.002. Epub 2021 Dec 8.
8
Adverse Cardiovascular Effects of Anti-COVID-19 Drugs.抗新冠病毒药物的心血管不良影响。
Front Pharmacol. 2021 Aug 25;12:699949. doi: 10.3389/fphar.2021.699949. eCollection 2021.
9
COVID-19, corticosteroids and public health: a reappraisal.COVID-19、皮质类固醇和公共卫生：重新评估。
Public Health. 2021 Aug;197:48-55. doi: 10.1016/j.puhe.2021.05.028. Epub 2021 Jun 7.
10
Active prescription of low-dose aspirin during or prior to hospitalization and mortality in COVID-19: A systematic review and meta-analysis of adjusted effect estimates.住院期间或之前积极开具低剂量阿司匹林处方与 COVID-19 患者死亡率：一项调整后效应估计的系统评价和荟萃分析。
Int J Infect Dis. 2021 Jul;108:6-12. doi: 10.1016/j.ijid.2021.05.016. Epub 2021 May 15.

本文引用的文献

1
Effect of chronic obstructive pulmonary disease and smoking on the outcome of COVID-19.慢性阻塞性肺疾病和吸烟对 COVID-19 结局的影响。
Int J Tuberc Lung Dis. 2020 Aug 1;24(8):838-843. doi: 10.5588/ijtld.20.0278.
2
The insidious threat of jamu and unregulated traditional medicines in the COVID-19 era.爪哇草药和不受监管的传统药物在新冠疫情时代的潜在威胁。
Diabetes Metab Syndr. 2020 Sep-Oct;14(5):895-896. doi: 10.1016/j.dsx.2020.06.022. Epub 2020 Jun 12.
3
Potential role of telemedicine in solving ST-segment elevation dilemmas in remote areas during the COVID-19 pandemic.远程医疗在新冠疫情期间解决偏远地区ST段抬高难题中的潜在作用。
Am J Emerg Med. 2021 Apr;42:242-243. doi: 10.1016/j.ajem.2020.06.012. Epub 2020 Jun 6.
4
Dexamethasone for COVID-19? Not so fast.地塞米松治疗 COVID-19？先别急。
J Biol Regul Homeost Agents. 2020;34(3):1241-1243. doi: 10.23812/20-EDITORIAL_1-5.
5
Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis.2019年冠状病毒病（COVID-19）严重患者的淋巴细胞减少症：系统评价与荟萃分析
J Intensive Care. 2020 May 24;8:36. doi: 10.1186/s40560-020-00453-4. eCollection 2020.
6
Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19-systematic review, meta-analysis, and meta-regression.脑血管病和心血管病对 COVID-19 死亡率和严重程度的影响：系统评价、荟萃分析和荟萃回归。
J Stroke Cerebrovasc Dis. 2020 Aug;29(8):104949. doi: 10.1016/j.jstrokecerebrovasdis.2020.104949. Epub 2020 May 14.
7
Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression.高血压与 COVID-19 肺炎的死亡率和疾病严重程度增加相关：系统评价、荟萃分析和荟萃回归。
J Renin Angiotensin Aldosterone Syst. 2020 Apr-Jun;21(2):1470320320926899. doi: 10.1177/1470320320926899.
8
Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis.皮质类固醇治疗对 SARS-CoV-2、SARS-CoV 或 MERS-CoV 感染患者结局的影响：系统评价和荟萃分析。
Leukemia. 2020 Jun;34(6):1503-1511. doi: 10.1038/s41375-020-0848-3. Epub 2020 May 5.
9
Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia - A systematic review, meta-analysis, and meta-regression.糖尿病与COVID-19肺炎患者的死亡率增加及疾病严重程度相关——一项系统评价、荟萃分析和Meta回归分析
Diabetes Metab Syndr. 2020 Jul-Aug;14(4):395-403. doi: 10.1016/j.dsx.2020.04.018. Epub 2020 Apr 17.
10
Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial.低剂量泼尼松在临床缓解超过 1 年的 SLE 患者中的撤药：一项随机临床试验。
Ann Rheum Dis. 2020 Mar;79(3):339-346. doi: 10.1136/annrheumdis-2019-216303. Epub 2019 Dec 18.